Verastem reported $-36.59M in Net Income for its fiscal quarter ending in March of 2026.





Net Income Change Date
AbbVie USD 3.61B 2.92B Jun/2026
Alaunos Therapeutics USD -1.01M 153K Mar/2026
AstraZeneca USD 2.51B 573M Jun/2026
Curis USD -24.2M 43.56M Mar/2026
Cytokinetics USD -206.03M 23M Mar/2026
Gilead Sciences USD 2.02B 162M Mar/2026
Incyte USD 585.6M 282.27M Jun/2026
Laboratory Of America USD 298.7M 20.9M Jun/2026
Novartis USD 3.26B 108M Jun/2026
Pfizer USD 2.69B 4.34B Mar/2026
Roche Holding CHF 6.87B 1.4B Jun/2026
TG Therapeutics USD 7.78M 12M Jun/2026
Verastem USD -36.59M 3.68M Mar/2026